Skip to main content
SpringerLink
Log in

The prognostic value of elevated ezrin in patients with osteosarcoma

  • Research Article
  • Published:
Tumor Biology

Abstract

Published studies researching the prognostic significance of ezrin expression in patients with osteosarcoma are inconclusive and heterogeneous. We conducted a meta-analysis to assess its prognostic value more precisely. The hazard ratios with corresponding 95 % confidence intervals were calculated to evaluate the effects. Five studies with 318 osteosarcoma patients were included to estimate the relationship between ezrin and disease-free survival, and ezrin and overall survival. Compared with osteosarcoma patients with low or negative ezrin expression, patients with high ezrin expression tended to be associated with lower disease-free survival, but the difference was not significant. However, patients with high ezrin expression were obviously associated with lower overall survival. Therefore, the findings from this systematic review suggest that ezrin expression is an effective biomarker of prognosis in patients with osteosarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21:vii320–5.

    Article  PubMed  Google Scholar 

  2. Niswander LM, Kim SY. Stratifying osteosarcoma: minimizing and maximizing therapy. Curr Oncol Rep. 2010;12:266–70.

    Article  PubMed  Google Scholar 

  3. Errani C, Longhi A, Rossi G, Rimondi E, Biazzo A, Toscano A, et al. Palliative therapy for osteosarcoma. Expert Rev Anticancer Ther. 2011;11:217–27.

    Article  PubMed  Google Scholar 

  4. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002;3:586–99.

    Article  CAS  PubMed  Google Scholar 

  5. Pujuguet P, Del Maestro L, Gautreau A, Louvard D, Arpin M. Ezrin regulates E-cadherin-dependent adherens junction assembly through Rac1 activation. Mol Biol Cell. 2003;14:2181–91.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman LJ. Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis. 2006;23:227–36.

    Article  CAS  PubMed  Google Scholar 

  7. Kanamori M, Sano A, Yasuda T, Hori T, Suzuki K. Array-based comparative genomic hybridization for genomic-wide screening of DNA copy number alterations in aggressive bone tumors. J Exp Clin Cancer Res. 2012;31:100.

    Article  CAS  PubMed  Google Scholar 

  8. Zhang H, Xu Y, Zhang Z, Liu R, Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Zhang H, Ma H, Xu Y, Li L. Association of SMAD7 rs12953717 polymorphism with cancer: a meta-analysis. PLoS One. 2013;8:e58170.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Zhang H, Li L, Xu Y. CYP1B1 polymorphisms and susceptibility to prostate cancer: a meta-analysis. PLoS One. 2013;8:e68634.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Zhang H, Ma H, Li L, Zhang Z, Xu Y. Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: a meta-Analysis. PLoS One. 2013;8:e69366.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Kim MS, Song WS, Cho WH, Lee SY, Jeon DG. Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res. 2007;459:229–36.

    Article  PubMed  Google Scholar 

  13. Salas S, Bartoli C, Deville JL, Gaudart J, Fina F, Calisti A, et al. Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas. Virchows Arch. 2007;451:999–1007.

    Article  CAS  PubMed  Google Scholar 

  14. Ferrari S, Zanella L, Alberghini M, Palmerini E, Staals E, Bacchini P. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma. Pediatr Blood Cancer. 2008;50:752–6.

    Article  PubMed  Google Scholar 

  15. Kim C, Shin E, Hong S, Chon HJ, Kim HR, Ahn JR, et al. Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat. 2009;41:138–44.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Boldrini E, Peres SV, Morini S, de Camargo B. Immunoexpression of ezrin and CD44 in patients with osteosarcoma. J Pediatr Hematol Oncol. 2010;32:e213–7.

    Article  CAS  PubMed  Google Scholar 

  17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    Article  PubMed  Google Scholar 

  18. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.

    CAS  PubMed  Google Scholar 

  19. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

    Article  CAS  PubMed  Google Scholar 

  20. Chen X, Tian HM, Yu XJ. Bone delivers its energy information to fat and islets through osteocalcin. Orthop Surg. 2012;4(2):114–7.

    Article  PubMed  Google Scholar 

  21. Dunn J, Dunn C, Habbu R, Bohay D, Anderson J. Effect of pregnancy and obesity on arch of foot. Orthop Surg. 2012;4(2):101–4.

    Article  PubMed  Google Scholar 

  22. Wang LJ, Yang HL, Shi YX, Jiang WM, Chen L. Pulmonary cement embolism associated with percutaneous vertebroplasty or kyphoplasty: a systematic review. Orthop Surg. 2012;4(3):182–9.

    Article  PubMed  Google Scholar 

  23. Malhotra P, Anwar M, Nanda N, Kochhar R, Wig JD, Vaiphei K, et al. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. Tumor Biol. 2013;34:1901–11.

    Article  CAS  Google Scholar 

  24. Krifa M, Alhosin M, Muller CD, Gies JP, Chekir-Ghedira L, Ghedira K, et al. Limoniastrum guyonianum aqueous gall extract induces apoptosis in human cervical cancer cells involving p16 INK4A re-expression related to UHRF1 and DNMT1 down-regulation. J Exp Clin Cancer Res. 2013;32:30.

    Article  PubMed  Google Scholar 

  25. Wikberg ML, Edin S, Lundberg IV, Van Guelpen B, Dahlin AM, Rutegård J, et al. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumor Biol. 2013;34:1013–20.

    Article  CAS  Google Scholar 

  26. Zhang H, Wang A, Ma H, Xu Y. Association between insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk. Tumor Biol. 2013. doi:10.1007/s13277-013-0855-3.

    Google Scholar 

  27. Adamo R, Comandini A, Aquino A, Bonmassar L, Guglielmi L, Bonmassar E, et al. The antiretroviral agent saquinavir enhances hTERT expression and telomerase activity in human T leukaemia cells in vitro. J Exp Clin Cancer Res. 2013;32:38.

    Article  CAS  PubMed  Google Scholar 

  28. Zhang H, Qi C, Li L, Luo F, Xu Y. Clinical significance of NUCB2 mRNA expression in prostate cancer. J Exp Clin Cancer Res. 2013;32:56.

    Article  PubMed  Google Scholar 

  29. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA. 1998;279:281–6.

    Article  CAS  PubMed  Google Scholar 

  30. Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA. 1992;267:374–8.

    Article  CAS  PubMed  Google Scholar 

  31. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867–72.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Spine Surgery, Weifang People’s Hospital, Guangwen Road, Kuiwen District, Weifang City, Shandong Province, 261041, China

    Deng-Xing Lun, Zhao-Wan Xu & Bin-Wu Wang

  2. Department of Bone Oncology, Tianjin Hospital, Tianjin, 300211, China

    Yong-Cheng Hu

  3. Department of Respiratory Medicine, Weifang People’s Hospital, Guangwen Road, Kuiwen District, Weifang City, Shandong Province, 261041, China

    Li-Na Xu

Authors
  1. Deng-Xing Lun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong-Cheng Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhao-Wan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Li-Na Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bin-Wu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yong-Cheng Hu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lun, DX., Hu, YC., Xu, ZW. et al. The prognostic value of elevated ezrin in patients with osteosarcoma. Tumor Biol. 35, 1263–1266 (2014). https://doi.org/10.1007/s13277-013-1168-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1168-2

Keywords

Search

Navigation